{"name":"Kineta","slug":"kineta","ticker":"KA","exchange":"NASDAQ","domain":"kinetabio.com","description":"Kineta is a beach town in West Attica, Greece. Since 2017 it is a separate community of the municipality Megara.","hq":"Seattle, WA","founded":0,"employees":"","ceo":"Shawn Bhatt","sector":"Immuno-Oncology / Pain","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$65M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":5387000,"netIncome":-17132000,"cash":1019000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"KTX-007 patent cliff ($0.0B at risk)","drug":"KTX-007","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Kineta Announces FDA Clearance of IND for KTX-007","summary":"Kineta received FDA clearance to initiate a Phase 1 clinical trial for KTX-007, its lead immuno-oncology candidate.","drugName":"KTX-007","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Kineta Reports Third Quarter 2023 Financial Results","summary":"Kineta reported revenue of $X.X million and a net loss of $Y.Y million for the third quarter of 2023.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2025-07-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOVTJLVlFHQnhEUlBYUkJUVXBEZmRrY0NJcjBiaVA3cFUxNkQwT3lKU2Q3NmF3TlRudUYxYXpiZUgxU2dGbGw5dkhvZ2RkS01aUHp5NG9obFpjRVFiQnN1NExHNUVrYk5ON3R1U2hCRUd6SjY1cDh2VWdPUldvODNRdXpCZDEzMzFMNUhmRnhTYmFKb2pQbVVJeGkzNm9RSi1FTTFaOA?oc=5","date":"2025-06-30","type":"pipeline","source":"Stock Titan","summary":"[S-8 POS] Kineta, Inc. Common Stock SEC Filing - Stock Titan","headline":"[S-8 POS] Kineta, Inc. Common Stock SEC Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE4wWG1paGo4b29sZDNDQ2ZkS2tQV2hKcWg4bkMtcXFwRnFhRkZTdmo0TktPUlltbVRwVWdISkVMYm0wYlNFcS1mRXk1VXN3SEsy?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KA Stock Price, News & Analysis - Stock Titan","headline":"KA Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9FeW4tbkQ5U0Q2RnJhRGRkM1ZEZUVHUERiNG1nNVVLVl9HX2wyRjRHZ1E2a043MVdNOG84cjNFMFlmVXBoNVhhNk9ndzRseUw0dzJEWTRPN1dJRS1I?oc=5","date":"2024-09-18","type":"pipeline","source":"ChartMill","summary":"KA Stock Price, Quote & Chart | KINETA INC (NASDAQ:KA) - ChartMill","headline":"KA Stock Price, Quote & Chart | KINETA INC (NASDAQ:KA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNNXlfOFBBalVHOUNFMmNXVTRKWTQtbkdYTTNZNWN2R1ZURndZblA3MERSeEVFemxHNWUwakRRVUpubkhXazJTazY2ZkVnZXJjUlFVcjZ0eW1yM0ZCOEFRX3NrWEZvdk92UlA5NFlrdVRfUjZPOUJNT0R2azQ4bjV4Z2pfTFpna3RydFEwcUE5MFpvYWIzOXNmLTlfMkJwUGVRZlNVd2J5ZVhBWWd0Y29YcWQ2dExuc08xblJ6RDFfWUtTQS1ocmtpRHFnQ04zclBUQWpkVkNmaXJud0NjY2RHamlEdkc4enBUNXFNVjNPc1NJWDI5NXB5eDBxc1N4Qi01VThUeWZyQllxN0VFUjJFZWdROTdiempFSTZnZVVodmJzUQ?oc=5","date":"2024-07-08","type":"pipeline","source":"PR Newswire","summary":"TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor - PR Newswire","headline":"TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VIS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNSXhsVVVBc05haV9McGp3QTZNR1FaWUVJNjBnTE96bEhqbWNiU0R1ekZzS1BlNHJiS0pSbU9SSzIxVWNqZFhxbmpkYUlyaV9icDFteDVxY1MzTUg5bjFFYmNxcDZ3akFseGd2NFVSQ1p0dHU4R1B2S29YSE10LV9QU19NZXpPV0poSWdLNFg1M3dVVWljVW5Ed3dRbG5wMHZ2Q2hIZXZESlBHcDNwRmRHWm41R2hIM2Uzc053?oc=5","date":"2024-01-17","type":"trial","source":"Stock Titan","summary":"Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors - Stock Titan","headline":"Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tum","sentiment":"neutral"}],"patents":[{"drugName":"KTX-007","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Bristol-Myers Squibb","Pfizer"],"therapeuticFocus":["Immuno-Oncology","Pain"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":0,"period":"2024-12-31"},{"value":5442000,"period":"2023-12-31"},{"value":5442000,"period":"2023-12-31"},{"value":1953000,"period":"2022-12-31"},{"value":1953000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5387000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17132000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1019000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}